Alembic Pharmaceuticals Limited has recommended a final dividend of ₹12 per equity share for the financial year ended March 31, 2026, the company informed NSE on May 15, 2026, following a board meeting that also approved quarterly financial results. The announcement marks a 9.1% increase over the ₹11 per share dividend paid in the previous two consecutive fiscal years.

Dividend Details and Yield

The board of directors approved the final dividend of ₹12 per share at face value, subject to shareholder approval. At the current market price of ₹786.10, this translates to a dividend yield of approximately 1.53%. The stock closed nearly flat on announcement day, up 0.05% at ₹786.10, with a trading volume of 87,340 shares.

Dividend History and Trend Analysis

The latest payout reflects a clear recovery and upward trajectory after a period of consolidation. A review of Alembic Pharmaceuticals' dividend history reveals the following per-share payouts:

After touching a low of ₹8 in FY23, the company has steadily raised its payout over three successive years, with FY26 marking the highest single final dividend since the ₹14 declared in FY21. The trend indicates improving cash generation and management's confidence in sustained earnings capacity.

Valuation and Market Context

Alembic Pharmaceuticals currently trades at a price-to-earnings (PE) ratio of 24.61, a modest premium to the sector PE of 23.31. This suggests the stock carries a slight valuation premium relative to its pharmaceutical sector peers listed on NSE, though the gap remains narrow. The company is a constituent of the NIFTY MICROCAP 250, NIFTY TOTAL MARKET, and NIFTY SMALLCAP 500 indices, with a market capitalisation of ₹15,451.83 Cr.

52-Week Range and Delivery Data

The stock is currently trading at ₹786.10, significantly below its 52-week high of ₹1,107.90 reached on June 30, 2025, and well above its 52-week low of ₹635.80 recorded on March 23, 2026. The current price represents a 29.1% discount from the yearly peak and a 23.6% premium over the yearly trough, positioning the stock in the lower half of its annual range.

Delivery percentage on the announcement date stood at 37.07% of total traded volume, against a daily volatility of 1.99%. A delivery percentage below 40% in the context of a dividend announcement typically indicates limited fresh institutional accumulation on the day, suggesting the payout news was either partially anticipated or did not trigger significant positional activity.

Company Background

Alembic Pharmaceuticals Limited is a Vadodara-based specialty pharmaceutical company with operations spanning domestic formulations, international generic markets, and active pharmaceutical ingredients. The company filed its financial results for the period ended March 31, 2026, alongside the dividend recommendation on May 15, 2026.

The final dividend will be subject to approval at the upcoming Annual General Meeting. Investors should monitor the record date announcement from the company for eligibility purposes.